Nachrichten zur Protalix BioTherapeutics Inc. Aktie

Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth

Protalix Biotherapeutics Inc (NYSE-A:PLX) said it is on track to launch a Phase II clinical trial of its experimental gout…

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipeline

Protalix Biotherapeutics Inc (NYSE-A:PLX) chairman Eliot Forster joined Proactive to discuss the companys unique approach to drug manufacturing using plant...…

Protalix Biotherapeutics gains momentum: analysts see long-term upside

Protalix Biotherapeutics Inc (NYSE-A:PLX) reported increased product revenues for 2024, driven by higher sales of its Fabry disease treatment, Elfabrio,…

Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate

Protalix Biotherapeutics Inc (NYSE-A:PLX) reported record revenue from product sales in 2024, driven by growth across all major commercial partnerships,…

Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum

For a small biotech company, Protalix Biotherapeutics Inc (NYSE-A:PLX) is making a big impression with analysts and investors by targeting…

Protalix Biotherapeutics gains momentum in the rare disease space: analysts

Protalix Biotherapeutics Inc (NYSE-A:PLX) has received bullish assessments from analysts at HC Wainwright and Zacks Small Cap Research, who see…

Protalix BioTherapeutics Inc. (PLX): H.C. Wainwright sieht 533 % Kurspotenzial!

Protalix BioTherapeutics Inc. (PLX) ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Herstellung von rekombinanten Proteinen zur Behandlung…